United States: Cannabusiness Investments: Evolving Risks And Due Diligence

Originally published by FINalternatives - Hedge Fund & Private Equity News, April 2015

With the legalization for medical use in 21 states, and for adult use in Colorado, Washington, Alaska and the District of Columbia (and Oregon, effective July 1, 2015), the cannabis industry is said to be the fastest growing industry in the United States. A rcview Market Research reported an increase in industry sales of 74 percent to $2.7 billion in 2014, up from $1.5 billion in 2013. As cultivation, distribution, medical and personal use become increasingly legal at the state level, entrepreneurs, their friends and family and other early-stage investors are starting to see pathways to harvest, following the influx of sophisticated investors from traditional private equity sources.

Over $100 million in private equity investments have been made over the last two years in cannabis-related businesses, according to CB Insights. The most recent sign the industry is coming of age is an investment from Peter Thiel's $2 billion Founders Fund, which has added Privateer Holdings to its impressive list of investments in Facebook, Airbnb and Spotify. Privateer's three portfolio companies are Tilray, Leafly, and Marley Natural.

Prospective investors should be aware of the unique risks presented by cannabis- related businesses. If due diligence is conducted properly, the "risk factors" section of an offering memorandum should not be news to the investor. From the company's perspective, thorough disclosure of risk factors will help manage expectations and prevent shareholder litigation. Any company planning a private securities offering in the United States should take care in clearly setting forth these risks in their disclosure documents. To date, many issuers of publicly traded microcap "pot stocks" that trade over the counter or on the pink sheets are not heeding this advice and some have declined to disclose any risk factors whatsoever, citing the lack of requirement for smaller reporting companies. It is not surprising that the SEC and FINRA have logged numerous complaints against these issuers and have even issued "investor alerts" warning the public about potential risks due to inaccurate disclosures.

This article presents some of the various risks that companies should disclose and some of the questions that investors should ask as a part of any offering of cannabis-related securities. A company's failure to disclose such risks, on the one hand, and an investor's failure to appreciate them, on the other hand, could result in ill-will, litigation, rescission, loss of investment, and, theoretically, even criminal prosecution. For some of these questions, there are no easy answers and an enquiring potential investor will gain valuable insight into how well prepared the entrepreneur is to handle the issues and communicate realistic answers.

The following is a list of risks that should be disclosed to potential investors:

1. Strict Enforcement of Federal Law

As states continue to decriminalize cannabis in a variety of ways, cannabis remains a "Schedule 1" controlled substance under the federal Controlled Substances Act, alongside heroin and methamphetamines. Accordingly, businesses that engage in various forms of commerce in the cannabis industry and individuals who purchase and use cannabis-derived products remain subject to federal prosecution and seizure of assets. The main risk for the investor is that federal enforcement could lead to dissolution and total loss of investment.

The Federal position on cannabis is rapidly changing, however. The spending bill passed by Congress in December, 2014, included a provision that prohibits federal agents from prosecuting patients or dispensaries that are operating in accordance with state laws authorizing the cultivation and use of cannabis for medicinal purposes in certain states. This provides little certainty for the longer term, as successive spending bills are temporary in nature and the next Congress can easily reinstate previous policies through spending.

In addition, several bills have been introduced in congress. On March 10, 2015, the bipartisan "Compassionate Access, Research Expansion, and Respect States (CARERS) Act", was introduced in the Senate which would classify cannabis as a Schedule II drug. This would mean that the U.S. government acknowledges that cannabis has legitimate use as a medicine. With respect to legal activities at the state level, the bill would also prevent federal law enforcement from prosecuting doctors and patients, and permit banking institutions to provide financial services to cannabis enterprises. Other pending bills include the "Marijuana Tax Revenue Act" (MTRA) and the "Regulate Marijuana Like Alcohol Act" (RMLAA). MTRA would impose a federal excise tax on retail cannabis sales, an occupational tax for cannabis businesses, and civil and criminal penalties for noncompliance. Under the RMLAA, the Bureau of Alcohol, Tobacco, Firearms and Explosives would provide oversight, and cannabis would be removed from the schedule of drugs enforced by the Drug Enforcement Agency.

Other bills being considered in congress include the "Respect State Marijuana Laws Act" , the "Ending Federal Marijuana Prohibition Act", the "States' Medical Marijuana Patient Protection Act", the "Truth in Trials Act" and the "States' Medical Marijuana Property Rights Protection Act" Entrepreneurs and investors should understand that there is no guaranty – or even discernible probability – that any of these bills will become law anytime soon, if ever.

The position of federal law enforcement is also changing. In a memorandum dated August 29, 2013, the U.S. Department of Justice released a memorandum indicating that it would not direct resources to block recreational and medical marijuana in "legal" states, relying on state enforcement for certain problem areas, such as sales to minors and driving under the influence.

The Department of Justice memorandum sets forth certain enforcement priorities that are important to the federal government, including distribution of products to children; diversion of medical marijuana from states where it is legal to states where it is not; preventing driving under the influence; growing marijuana on federal property; and preventing possession or use of marijuana on federal property.

Investors should take note that the Department of Justice's stance on this issue could change quickly with a new administration in Washington, or even sooner – during her January, 2015 confirmation hearings before the Senate Judiciary Committee, Attorney General Nominee Loretta Lynch testified that she does "not support the legalization of marijuana" and that she does not share the President's view that it is not more dangerous than alcohol.

One issuer disclosed the following risk to its investors:

"Further, and while we do not intend to harvest, distribute or sell cannabis, by supplying products to growers of marijuana, we could be deemed to be participating in marijuana cultivation, which remains illegal under federal law, and exposes us to potential criminal liability, with the additional risk that our business could be subject to civil forfeiture proceedings.

Another issuer characterized this risk as follows:

"Growing medical marijuana is deemed to be illegal under the Federal Controlled Substances Act even though such activities may be permissible under state law. A theoretical risk exists that our activities could be deemed to be facilitating the selling or distribution of marijuana in violation of the federal Controlled Substances Act, or to constitute aiding or abetting, or being an accessory to, a violation of that Act."

Another issuer disclosed the following:

"Currently, there are 23 states plus the District of Columbia that have laws and/ or regulations that recognize, in one form or another, legitimate medical uses for cannabis and consumer use of cannabis in connection with medical treatment. Many other states are considering similar legislation. Conversely, under the Controlled Substance Act (the "CSA"), the policies and regulations of the Federal government and its agencies are that cannabis has no medical benefit and a range of activities including cultivation and the personal use of cannabis is prohibited. Unless and until Congress amends the CSA with respect to medical marijuana, as to the timing or scope of any such potential amendments there can be no assurance, there is a risk that federal authorities may enforce current federal law, and we may be deemed to be producing, cultivating or dispensing marijuana in violation of federal law."

In December, the attorneys general of Nebraska and Oklahoma sued Colorado, seeking to strike down parts of Colorado's legalization of cannabis for adult use. They claim that Colorado's legal marijuana is crossing state lines and causing harm to their states where cannabis remains illegal by "placing stress on their criminal justice systems" and "draining their treasuries".

One issuer disclosed the following related risk to its investors:

"Our website is visible in jurisdictions where medicinal and/or recreational use of marijuana is not permitted and, as a result, we may be found to be violating the laws of those jurisdictions. We could lose potential customers as they could fear federal prosecution for growing marijuana with our equipment, reducing our revenue. In most states in which the production and sale of marijuana have been legalized, there are additional laws or licenses required and some states altogether prohibit home cultivation, all of which could make the loss of potential customers more likely."

Some related questions a prospective investor should ask about law enforcement:

  • Has the business been contacted by any state or federal law enforcement or regulatory agencies?
  • Does the business have any contingency plans in the event of strict enforcement of federal law?
  • How easily can the business pivot to another line of business?
  • How many customers are from out of state? How do you ensure that they do not cross state lines with your product? Do you have an obligation to warn customers about this or take steps in prevention them from doing so?

2. No Adequate Banking Solution

Banking services are something that most entrepreneurs take for granted, but that is not the case for businesses that deal in cannabis products and services. Often cited as the biggest problem in the legal cannabis industry, banks are not yet willing to take deposits, issue credit cards, open checking accounts, or assist with payroll services. Banks have been reluctant to engage cannabis-related businesses out of fear of violating federal law and being accused of money laundering. One bank even reversed course after touting the FDIC's "tacit" approval. After Oregon-based Mbank community bank was contacted by "federal banking regulators", it promptly ceased welcoming customers from Colorado. This reversal did no go unnoticed on Capitol Hill, as U.S. Rep. Earl Blumenauer is seeking to uncover the FDIC's role in this matter. In November, 2014, another banking institution, Colorado- based Fourth Corner Credit Union, received its state charter from the Colorado Division of Financial Services, but it is still waiting for approval from the U.S. Federal Reserve while it seeks insurance from another department, the National Credit Union Administration.

Until the banking question is resolved, cannabis businesses are handling lots of cash, which presents numerous risks, including inability to secure and invest funds, manage cash flows, and pay taxes; safety/security risks and expenses; and crimes such as theft, assault, burglary, employee skimming, and tax evasion.

One issuer disclosed the following:

"We may have difficulty accessing the service of banks, which may make it difficult for us to operate. Since the use of marijuana is illegal under federal law, there is a strong argument that banks cannot accept for deposit funds from businesses involved with the marijuana industry. Consequently, businesses involved in the marijuana industry often have difficulty finding a bank willing to accept their business. The inability to open bank accounts may make it difficult for us to operate our contemplated medical marijuana business in Nevada."

Another issue disclosed:

"[S]ince the use of marijuana is illegal under federal law, we may have difficulty acquiring or maintaining bank accounts and insurance and our shareholders may find it difficult to deposit their stock with brokerage firms."

Some questions that a prospective investor should ask about banking:

  • How does the company do its banking? How will your cash flow from investing activities be impacted if no brokerage firm will do business with you?
  • Does the company pay its taxes, salaries and other operating expenses in cash?
  • How does the company manage the risks presented with handling so much cash? How is cash-flow tracked and managed?
  • What expenses are associated with this issue?

3. Compliance with State Laws and Regulations

Companies are subject to changing laws and regulations in their home states and in the states in which they do business. As the legal cannabis industry is in its infancy, participants should try to anticipate new rules and how they might affect their businesses. Rapidly changing laws can create numerous expenses for a growing business and enable "fast-followers" to gain a competitive advantage by learning from the early entrant's mistakes. Increased regulatory compliance costs could result in lower gross margins or higher retail prices, or both, while competition from the black market looms.

Regulations also have unintended consequences that present risks to a company and its investors. For example, in Colorado "medical marijuana" is often less expensive, more potent and available to the patient in larger quantities than its recreational counterpart. Conversely, the process of obtaining recreational products in Colorado is more private as regulations do not require third parties (e.g., a doctor) and impose fewer record retention requirements. These differences may cause a patient to purchase recreational cannabis, and vice versa.

Some questions to ask about compliance:

  • Does the company participate in any industry trade associations?
  • Has a lobbyist been engaged?
  • How will the company respond to changes in regulations or specific laws?
  • Is there pending legislation that will adversely affect the business?
  • How do prices compare to black market prices?

A prospective investor should understand whether the company is in compliance with state law and should ask questions about this. For example, Colorado requires a person to have been a resident of the state for two years before applying for a license, and it requires equity investors (and holders of convertible debt) to be residents. Washington state also has a residency requirement for the entrepreneur.

The penalties for violations of these regulations are unclear, and an investor should insist that the company represents in the transaction documents that it is in compliance with state laws.

4. Federal Tax Law Challenges

Except for "cost of goods sold," Section 280E of the Internal Revenue Code prohibits cannabis businesses from taking tax deductions for numerous ordinary and necessary business expenses. This should not be a surprise to the cannabis entrepreneur who is seeking capital from investors. A business's inability to take advantage of deductions for ordinary business expenses significantly hurts profit margins and may cause investors to think twice about investing. A business's financial statements and projections of after-tax profits should take this into account. How the target handles this issue in its solicitation materials could help a prospective investor gauge an entrepreneur's sophistication or naïveté.

5. Product Liability Claims

Insurance law for cannabis related risks is not developed, and product liability lawsuits against manufacturers of cannabis products are a top concern. Accordingly, investors and companies should review their policies with counsel and understand that coverages may be limited or challenged by insurance carriers, despite what a policy might provide.

One issuer disclosed the following risk to its investors:

"We are subject to the risk of product liability claims and the loss of any such claim in excess of our insurance coverage could have a material adverse effect on our business and financial condition."

Some questions that should be asked about products liability risks.

  • What testing has been conducted to ensure consistency?
  • Have there been any complaints? Has anyone been harmed?
  • What insurance is available? Is it adequate for the particular risks of this company? How much insurance has the company purchased?
  • You sell lollipops infused with THC. How do you prevent the lollipops from being ingested by children? Have you received any complaints?

6. Background Checks

An investor should not be surprised if a cannabis entrepreneur developed his or her interest and expertise long before legalization. It is therefore wise to conduct criminal background checks on the founding team. An arrest for possession during a decade-old frat party may be overlooked, but if a member of the founding team, for example, served time in prison for numerous violations, the investor should seriously consider passing on the opportunity.

7. Market Acceptance

Even if a majority of voters support adult non-medical use of cannabis products, retailers and distributors may be reluctant to carry them for a variety of reasons. One common mistake that entrepreneurs make is the belief that their product is so good that it will "sell itself". Cannabis products are no exception, and have the added challenge of convincing retail partners to carry their products.

One issuer disclosed the following risk:

"Due to the general negativity associated with the cannabis plant within the United States, we anticipate facing potential challenges getting our products into stores."

Some related questions a potential investor should ask:

  • How many retailers carry your product?
  • What is your marketing strategy? / How do you market to retailers?
  • What are the challenges in getting your products on store shelves?


Of course, the foregoing are only some of the risks that a prospective investor should consider. Risks may also arise in connection with oversupply (which has been reported in Washington State), intellectual property (inability to register a federal trademark), lower-priced competition from the black market, labor issues, and of course, more general risks arising from agricultural, supply chain, employment, and economic/market conditions. Many more risks that prudent investors should be aware of and companies should disclose will certainly develop along with the industry and changing law. Identifying and anticipating such risks will add tremendous value to risk mitigation efforts.

The views expressed herein are those of the author and do not necessarily reflect the views or positions of Anderson Kill PC, any of its affiliates or other attorneys, or any of its clients. This article is for general information purposes only, in a changing legal environment. It is not intended to be, nor should it be construed as, legal advice to any person or entity for any particular factual context.

Andrew M. Walsh is an attorney in Anderson Kill's Stamford office and a member of the firm's Corporate and Securities, Regulated Products and Captive Insurance groups. Mr. Walsh advises entrepreneurs, emerging companies and private equity investors in company formation, capitalization, mergers and acquisitions, commercial transactions and corporate governance. As a member of Anderson Kill's Regulated Products group, he counsels startups engaged in cannabis-related business. awalsh@andersonkill.com

About Anderson Kill

Anderson Kill practices law in the areas of Insurance Recovery, Commercial Litigation, Environmental Law, Estate, Trusts and Tax Services, Corporate and Securities, Antitrust, Banking and Lending, Bankruptcy and Restructuring, Real Estate and Construction, Foreign Investment Recovery, Public Law, Government Affairs, Employment and Labor Law, Captive Insurance, Intellectual Property, Corporate Tax, Hospitality, and Health Reform. Recognized nationwide by Chambers USA for Client Service and Commercial Awareness, and best-known for its work in insurance recovery, the firm represents policyholders only in insurance coverage disputes - with no ties to insurance companies and has no conflicts of interest. Clients include Fortune 1000 companies, small and medium-sized businesses, governmental entities, and nonprofits as well as personal estates. Based in New York City, the firm also has offices in Ventura, CA, Philadelphia, PA, Stamford, CT, Washington, DC, Newark, NJ and Dallas, TX.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions